Search research articles
Contact Us
Filters
Showing results (151-160 of 200) with videos related to
Page
of 20
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 11, 2016
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Silke Heidenreich, Dimitris Ziagkos, Liesbeth C de Wreede, et al.
Leukemia
|
November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Bone Marrow Transplantation
|
January 22, 2024
Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
María Queralt Salas, Diderik-Jan Eikema, Linda Koster, et al.
Leukemia
|
July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Hemasphere
|
August 18, 2025
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party
Philipp Berning, Maud Ngoya, Won Seog Kim, et al.
Blood
|
January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Lisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Bone Marrow Transplantation
|
November 12, 2024
Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Kavita Raj, Diderik-Jan Eikema, Sarah Lawless, et al.
British Journal of Haematology
|
July 10, 2018
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO
Irit Avivi, Luca Arcaini, Virginia V Ferretti, et al.
Bone Marrow Transplantation
|
May 15, 2023
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature
Marie Robin, Luuk Gras, Linda Koster, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 200) with videos related to
Sort By:
Page
of 20
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 11, 2016
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Silke Heidenreich, Dimitris Ziagkos, Liesbeth C de Wreede, et al.
Leukemia
|
November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Bone Marrow Transplantation
|
January 22, 2024
Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
María Queralt Salas, Diderik-Jan Eikema, Linda Koster, et al.
Leukemia
|
July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Hemasphere
|
August 18, 2025
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party
Philipp Berning, Maud Ngoya, Won Seog Kim, et al.
Blood
|
January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Lisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Bone Marrow Transplantation
|
November 12, 2024
Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Kavita Raj, Diderik-Jan Eikema, Sarah Lawless, et al.
British Journal of Haematology
|
July 10, 2018
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO
Irit Avivi, Luca Arcaini, Virginia V Ferretti, et al.
Bone Marrow Transplantation
|
May 15, 2023
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature
Marie Robin, Luuk Gras, Linda Koster, et al.
Page
of 20